Allergan Restasis Antitrust

DEFENDANT NAME: Allergan, Inc.
STOCK SYMBOL:
CASE NUMBER: 18-md-02819
CASE NAME:
COURT: U.S. District Court for the Eastern District of New York
STATUS:
CLASS PERIOD:
LEAD PLAINTIFF DEADLINE:
DATE FILED: 11/17/17
COURT LOCATION:
RELATED DOCUMENTS:
CONTACT:

CASE UPDATE

Motion to dismiss was denied on September 18, 2018. The parties are currently negotiating discovery responses and document review is ongoing.

The court appointed HBSS interim lead counsel of a proposed class of direct purchasers of the Allergan, Inc. dry-eye emulsion, Restasis.  The purchasers allege the following that Allergan fraudulently obtained a series of patents for Restasis by misrepresenting that clinical trials newly showed that a lower strength Restasis formulation worked better than a stronger version.  After securing these patents through fraud, Allergan then wrongly enforced those patents by listing them in the FDA’s Orange Book and filing sham litigations against potential generic competitors.  Allergan also tried to circumvent the judicial process by selling its patent rights to the St. Regis Mohawk Tribe (which immediately licensed the patents back to Allergan) and claiming tribal immunity.  Lastly, Allergan filed a series of sham citizen petitions with FDA asserting that FDA’s standards for ANDA approval were insufficient.  These petitions delayed FDA from reviewing generic Restasis ANDAs and caused the approval of generic Restasis to be delayed.

On September 18, 2018, the Court denied Allergan’s Motion to Dismiss the purchasers’ complaint for failure to allege causation. Discovery is underway with trial set for January 2020.

--

In re Restasis (Cyclosporine Ophthalmic Emulsion) Antitrust Litigation


Hagens Berman purchases advertisements on search engines, social media sites and other websites. Transmission of the information contained or available through this website is not intended to create, and receipt does not constitute, an attorney-client relationship. If you seek legal advice or representation by Hagens Berman, you must first enter a formal agreement. All information contained in any transmission is confidential and Hagens Berman agrees to protect information against unauthorized use, publication or disclosure. This site is regulated by the Washington Rules of Professional Conduct.

Back to all cases

Case videos

Case Gallery

Case Timeline

09/18/18: CASE UPDATE

Motion to dismiss was denied on September 18, 2018. The parties are currently negotiating discovery responses and document review is ongoing.

04/04/18: Consolidated Amended Complaint Filed

After several direct and indirect purchaser cases were consolidated in the Eastern District of New York, direct purchasers filed their consolidated amended class action complaint on April 4, 2018.

11/17/17: Active

Complaint filed

Related News